Advanced Therapies, Llc

Advanced Therapies is a cell therapy Contract Testing, Development and Manufacturing Organization (CTDMO.) We leverage our significant experience and proven track record in development and manufacturing, as well as expert testing services, to enable advanced therapies to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities and cost of high-touch, multi-vendor production models. On 7 March 2025, Advanced Therapies U.S. and our discovery arm, OXGENE were purchased by Altaris, an investment firm headquartered in the U.S. with an exclusive focus on the healthcare industry. With a 20+ year track record that includes 11 medical product CDMOs, Altaris is well-positioned to support Advanced Therapies over its next phase of growth. This transaction builds on Altaris’ strategic initiative for the cell and gene therapy market, which is focused on delivering life-changing therapies to patients at scale. As part of this strategy, Altaris acquired Minaris Regenerative Medicine (“Minaris”) from Resonac Holdings Corporation in January of this year. Minaris is a cell therapy contract development and manufacturing organization (CDMO) with operations in the United States, Germany and Japan. Altaris intends to combine Advanced Therapies and Minaris into a single company, Minaris Advanced Therapies. The combined company’s extensive track record, breadth of capabilities and global manufacturing footprint will enhance our ability to service our customers, accelerate development timelines, reduce manufacturing costs, and improve patient access to life-saving treatments. For now, Minaris and Advanced Therapies will continue to operate as two independent companies to ensure business continuity until the completion of certain separation milestones from their respective former parent companies. We expect them to be fully combined by the end of 2025.